• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 28, 2013

View Archived Issues

Sangamo Adds Gene Therapy Assets with Ceregene Buyout

Sangamo BioSciences Inc., of Richmond, Calif., will acquire a Phase II Alzheimer’s disease gene therapy, CERE-110, plus a device for brain delivery with its acquisition of San Diego-based Ceregene Inc. Sangamo agreed to hand over 100,000 shares of its common stock, plus a payout on revenues from its products. Read More

'Ruble' Slippers: Russian Cash in Argos' $42M Phase III Raise

Argos Therapeutics Inc.’s Series E financing – which has raised $42.5 million so far, including $30 million from the venture arm of a Russian pharma firm – is staying open and could turn into enough for the company to finish its pivotal Phase III trial with AGS-003, a personalized immunotherapy for metastatic kidney cancer. Read More

Syndax Secures a Sweet $26.6M Series B

Syndax Pharmaceuticals Inc. moved closer to a new drug application (NDA)-enabling Phase III trial of lead candidate entinostat in metastatic breast cancer with a $26.6 million Series B financing. Read More

BIA: Investment at Risk in UK’s Value-Based Pricing

LONDON – As the summer break comes to an end, the industry in the UK is bracing itself for the outcome of government deliberations on establishing a value-based pricing system for drugs, with the Bioindustry Association (BIA) warning that investment in biotech could be put at risk. Read More

Other News To Note

• Carolus Therapeutics Inc., of San Diego, and The Alpha-1 Project Inc. (TAP), a wholly owned subsidiary of the Alpha-1 Foundation, are collaborating to characterize human biological samples for the presence of the target, RANTES:PF4 heterodimer, a soluble protein complex that is secreted by activated platelets and implicated in many inflammation-related diseases, including genetic emphysema and chronic obstructive pulmonary disease. Read More

Stock Movers

Read More

Clinic Roundup

• Lipidor AB, of Stockholm, a Karolinska Development portfolio firm, reported results from a Phase I/IIa study of AKVANO/calcipotriol spray formulation for the treatment of psoriasis vulgaris, which showed that the water-free spray had clear and significant antipsoriatic effects vs. placebo, comparable to a marketed formulation of calcipotriol, meeting the primary objective of the study. Read More

Washington Roundup

• The FDA released a draft guidance for abbreviated new drug applications (ANDAs) for stability testing of drug substances and products including responses to public comments, particularly with respect to recommendations for generic drug manufacturers to follow International Conference on Hamonisation stability guidances. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe